P
59.61
-1.48 (-2.42%)
| Previous Close | 61.09 |
| Open | 61.45 |
| Volume | 480,707 |
| Avg. Volume (3M) | 1,257,320 |
| Market Cap | 4,735,304,704 |
| Price / Earnings (TTM) | 8.46 |
| Price / Sales | 2.83 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 33.56% |
| Operating Margin (TTM) | 82.43% |
| Diluted EPS (TTM) | 6.39 |
| Quarterly Revenue Growth (YOY) | 459.70% |
| Current Ratio (MRQ) | 3.89 |
| Operating Cash Flow (TTM) | 691.65 M |
| Levered Free Cash Flow (TTM) | 526.00 M |
| Return on Assets (TTM) | 24.42% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | PTC Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.3
| Analyst Consensus | 1.5 |
| Insider Activity | -4.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.30 |
|
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.40% |
| % Held by Institutions | 101.06% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 118.00 (Cantor Fitzgerald, 97.95%) | Buy |
| Median | 73.00 (22.46%) | |
| Low | 46.00 (Barclays, -22.83%) | Hold |
| Average | 73.67 (23.59%) | |
| Total | 7 Buy, 2 Hold | |
| Avg. Price @ Call | 48.85 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 03 Sep 2025 | 118.00 (97.95%) | Buy | 55.55 |
| 29 Jul 2025 | 120.00 (101.31%) | Buy | 49.29 | |
| B of A Securities | 20 Aug 2025 | 76.00 (27.50%) | Buy | 48.85 |
| 29 Jul 2025 | 84.00 (40.92%) | Buy | 49.29 | |
| Morgan Stanley | 20 Aug 2025 | 71.00 (19.11%) | Buy | 48.85 |
| Wells Fargo | 20 Aug 2025 | 73.00 (22.46%) | Buy | 48.85 |
| 08 Aug 2025 | 79.00 (32.53%) | Buy | 45.38 | |
| RBC Capital | 08 Aug 2025 | 63.00 (5.69%) | Buy | 45.38 |
| Barclays | 29 Jul 2025 | 46.00 (-22.83%) | Hold | 49.29 |
| Truist Securities | 29 Jul 2025 | 86.00 (44.27%) | Buy | 49.29 |
| UBS | 29 Jul 2025 | 80.00 (34.21%) | Buy | 49.29 |
| Citigroup | 28 Jul 2025 | 50.00 (-16.12%) | Hold | 44.34 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PAUWELS ERIC | - | 56.95 | -39,850 | -2,269,458 |
| SOUTHWELL DAVID P | - | 58.42 | -12,000 | -701,040 |
| Aggregate Net Quantity | -51,850 | |||
| Aggregate Net Value ($) | -2,970,498 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 57.69 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SOUTHWELL DAVID P | Director | 09 Sep 2025 | Sell (-) | 12,000 | 58.42 | 701,040 |
| SOUTHWELL DAVID P | Director | 09 Sep 2025 | Option execute | 12,000 | - | - |
| PAUWELS ERIC | Officer | 08 Sep 2025 | Automatic sell (-) | 39,850 | 56.95 | 2,269,458 |
| PAUWELS ERIC | Officer | 08 Sep 2025 | Option execute | 39,850 | - | - |
| Date | Type | Details |
|---|---|---|
| 21 Aug 2025 | Announcement | PTC Therapeutics to Participate at Upcoming Investor Conferences |
| 19 Aug 2025 | Announcement | PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA |
| 07 Aug 2025 | Announcement | PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results |
| 28 Jul 2025 | Announcement | PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) |
| 21 Jul 2025 | Announcement | PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results |
| 23 Jun 2025 | Announcement | Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) |
| 19 Jun 2025 | Announcement | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |